文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危前列腺癌盆腔淋巴结照射联合MRI引导SBRT微推量毒性研究

Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity.
PubMed 文献 · Adv Radiat Oncol · 2026-02-13

本研究评估高危前列腺癌患者接受盆腔淋巴结照射后行3次SBRT前列腺精囊推量,其中15例同时接受MRI引导的前列腺内病灶消融微推量(MIB)额外2300 cGy/3次。中位随访8.7个月,MIB与非MIB亚组急性和晚期GI及GU毒性分布无显著差异,仅非MIB组出现2例3级毒性。结论提示MRI引导SBRT MIB未增加GI毒性,甚至可能降低GU毒性。

要点

  • 高危前列腺癌盆腔淋巴结照射后3次SBRT推量,加MRI引导微推量未显著增加GI/GU毒性。
  • 仅非MIB组出现2例3级毒性,两组2级及以上GI/GU毒性无显著差异。
  • 中位随访仅8.7个月,长期副作用和肿瘤学结局需进一步研究。

核心结论

  • 早期随访中,MIB与非MIB组急性和晚期GI及GU毒性分布无显著差异。
  • MRI引导SBRT MIB未增加GI毒性,甚至可能降低GU毒性。

研究设计与样本

  • 回顾性分析2021年4月至2023年3月机构登记的前列腺癌患者,均接受盆腔淋巴结照射后3次SBRT前列腺精囊推量。
  • 前列腺SBRT推量剂量主要为2100 cGy/3次(可接受范围1800-2100 cGy),毒性按CTCAE v5.0评估。

主要发现

  • 风险分组:高危36.2%(n=21),极高危34.5%(n=20),已知淋巴结病变19.0%(n=11),中危10.3%(n=6)。
  • 中位随访8.7个月,MIB与非MIB亚组急性(<90天)和晚期(>90天)GI及GU毒性分布无显著差异。
  • 共观察到2例3级毒性,均发生在非MIB队列;两组2级及以上GI和GU毒性无显著差异。

关键数值与推荐

  • 前列腺SBRT推量剂量主要为2100 cGy/3次,可接受范围1800-2100 cGy。
  • MIB额外剂量为2300 cGy/3次,范围2100-2400 cGy。
  • 毒性分级采用NCI CTCAE version 5.0。

临床怎么用

  • 对于高危前列腺癌患者,盆腔淋巴结照射联合3次SBRT前列腺推量时,可考虑同步MRI引导病灶微推量而不显著增加早期GI/GU毒性。
  • 需注意目前随访时间较短,长期毒性和肿瘤学获益尚未明确。

局限性

  • 中位随访仅8.7个月,无法评估长期毒性。
  • 未报告EPIC评分和肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent publications have renewed interest in prophylactic pelvic radiation therapy for higher-risk prostate cancer, as well as dose escalation for magnetic resonance imaging (MRI)-defined intraprostatic lesions. Here, we explore the use of pelvic nodal irradiation with a 3-fraction stereotactic body radiation therapy (SBRT) boost to the prostate and seminal vesicles, with a simultaneous MRI-directed focal intraprostatic lesion-ablative microboost (MIB). METHODS AND MATERIALS: We evaluated an institutional registry of patients undergoing pelvic nodal radiation followed by an SBRT boost to the prostate and seminal vesicles from April 2021 to March 2023. The study was approved by the local institutional review board (study #00001269). All patients were treated with pelvic nodal irradiation followed by a 3-fraction SBRT boost. The prostate SBRT boost dose was primarily 2100 cGy in 3 fractions (an accommodated range of 1800-2100 cGy). A subgroup of 15 patients received an MIB to an additional dose of 2300 cGy in 3 fractions (range, 2100-2400 cGy). The distribution of adverse event grades for acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. RESULTS: Fifty-eight patients underwent pelvic nodal irradiation followed by an SBRT boost to the prostate, with the distribution of risk groups as follows: patients were either in the high (36.2%, n = 21) or very high (34.5% n = 20) risk groups, whereas those with known nodal disease (19.0%, n = 11) or intermediate risk (10.3%, n = 6) comprised the rest of the study population. Most patients received androgen-deprivation therapy. The prostate SBRT boost dose was primarily 2100 cGy in 3 fractions. Fifteen patients received an MIB to an additional dose of 2300 cGy in 3 fractions. A median follow-up of 8.7 months was used to document the incidence of GU and GI toxicity. The distribution of GI and GU toxicity showed no significant difference between the MIB and non-MIB subcohorts at either the acute (<90 days) or late (>90 days) time points. Two grade 3 toxicities were observed, both in the non-MIB cohort. Grade 2+ GI and GU toxicities were not significantly different between the 2 groups, as assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. CONCLUSIONS: In the early follow-up period, we observed no significant difference in GI or GU toxicity between those who underwent MIB and those who did not. These results suggest that MRI-directed SBRT MIB did not increase GI toxicity and may even reduce GU toxicity compared with standard treatment. Future research should explore long-term side effects, with attention to the Expanded Prostate Cancer Index Composite (EPIC) scores and oncologic outcomes of this novel method of dose escalation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Musthafa M, Wells M, Kearney T, et al. Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity. Adv Radiat Oncol. 2026. PMID: 41809561. doi:10.1016/j.adro.2026.101997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。